November 20, 2018
Amgen Astellas Biopharma said on November 19 that its investigational agent for the prevention of episodic migraine, erenumab, met the primary endpoint in a PII study conducted in Japanese patients. In the placebo controlled study, 475 Japanese patients, who experienced...read more